Apogee Therapeutics is a biotechnology company focused on developing innovative therapies for autoimmune and inflammatory diseases. Its core products include monoclonal antibodies and other biologics aimed at modulating immune responses. The company operates primarily in the healthcare sector, with major revenue sources stemming from research collaborations, grants, and potential future product sales.
The investment profile of Apogee Therapeutics is more aligned with growth investors, given its focus on developing novel therapies and the potential for significant market opportunities. The company is in an early stage of development, which may appeal to those looking for high-risk, high-reward scenarios. Investors should consider their risk tolerance and investment horizon when evaluating this stock.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-08-05 | Sell | Hold | Weak fundamentals and high risk limit upside potential. |
| 2026-07-23 | Hold | Sell | Weak fundamentals and high volatility raise significant concerns. |
| 2026-06-25 | — | Hold | Strong recent performance, but fundamentals remain weak. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-06-24 | Stifel Nicolaus | Rating Downgraded | — → 135 | 132.97 |
| 2026-06-24 | Mizuho Securities | Update | — → 135 | 132.88 |
| 2026-06-23 | RBC Capital | Rating Downgraded | — → 135 | 132.55 |
| 2026-06-23 | UBS | Rating Downgraded | — → 135.11 | 132.55 |
| 2026-06-22 | Deutsche Bank | Rating Downgraded | — → 135 | 132.55 |
| 2026-06-22 | Craig-Hallum | Rating Downgraded | — → 135.11 | 132.647 |
| 2026-06-08 | RBC Capital | Target Raised | — → 97 | 86.92 |
| 2026-05-28 | Goldman Sachs | Update | — → 89 | 77.5 |
| 2026-05-27 | Truist Financial | Target Lowered | 83 → 81 | 78.07 |
| 2026-05-27 | Wedbush | Target Raised | 120 → 135 | 81.725 |
| 2026-05-01 | Redburn Partners | Update | — → 140 | 82.89 |
| 2026-03-17 | Truist Financial | Update | — → 83 | 69.85 |
| 2026-02-02 | Jefferies | Target Lowered | — → 95 | 65.99 |
| 2026-01-22 | RBC Capital | Rating Downgraded | — → 83 | 81.91 |
